SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th

Rhea-AI Summary

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced that CEO Angelos Stergiou will present at the 2021 Cantor Global Healthcare Conference on September 28, 2021, at 4:00 p.m. ET. The company specializes in developing innovative cancer immunotherapies, notably its lead candidate galinpepimut-S (GPS), which targets the WT1 protein in various tumors, and nelipepimut-S (NPS), aimed at early-stage breast cancer patients. For further details about the conference or to arrange meetings, interested parties can contact Cantor representatives or KCSA Strategic Communications.

NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS, will present at the 2021 Cantor Global Healthcare Conference to be held virtually on Tuesday, September 28, 2021, at 4:00 p.m. ET.

For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to Cantor at corporateaccess@cantor.com or KCSA Strategic Communications at SELLAS@kcsa.com.

About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.

For more information on SELLAS, please visit www.sellaslifesciences.com.

For more information, please contact:

Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707

Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276

FAQ

What is the date and time of SELLAS Life Sciences' presentation at the Cantor Global Healthcare Conference?

SELLAS Life Sciences will present on September 28, 2021, at 4:00 p.m. ET.

Who is presenting for SELLAS Life Sciences at the conference?

Angelos Stergiou, the CEO of SELLAS Life Sciences, will present at the conference.

What are the main products developed by SELLAS Life Sciences?

SELLAS Life Sciences is focused on galinpepimut-S (GPS), targeting the WT1 protein, and nelipepimut-S (NPS) for HER2-positive early-stage breast cancer.

How can I schedule a meeting with SELLAS management during the conference?

To schedule a meeting, contact your Cantor representative or email corporateaccess@cantor.com or SELLAS@kcsa.com.

What is the focus area of SELLAS Life Sciences Group, Inc.?

SELLAS is focused on developing novel cancer immunotherapies for various cancer indications.